Patent Evaluation: Novel Imidazol[2,1-b]thiazole Derivatives as Anti-ulcer Agents

Summary

Novelty: Novel imidazol[2,1-b]thiazole derivatives, said to exhibit gastric acid secretion inhibiting activity, are disclosed. The compounds are potentially useful as anti-ulcer agents and possess very low toxicity.

Biology: The compounds were evaluated for anti-ulcer activity against the following models: aspirin-induced, water-immersion, stress-induced and ethanol induced, and rodent ulcer. The compounds were also evaluated for their gastric juice secretion inhibition activity and for their toxicity. A selected compound gave inhibition rates of over 40% in all ulcer models.

Chemistry: 5-(1-Hydroxybutyl)-6-methylimidazo[2,1-b]-thiazole is one of three specifically claimed compounds.

Structure: